The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).
 
Rosario Garcia Campelo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche; Takeda
 
Huamao Mark Lin
Employment - Change HealthCare; Change HealthCare (I); Takeda; Takeda (I)
Stock and Other Ownership Interests - Takeda
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
 
Mohammad Jahanzeb
Honoraria - Foundation Medicine
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - Foundation Medicine
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Callisto Pharmaceuticals (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Foundation Medicine; Helsinn Therapeutics
 
Sanjay Popat
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Guardant Health; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Epizyme (Inst); Lilly (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme
 
Yanyan Zhu
Employment - Takeda
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Alnylam; Biogen (I); Biomarin; Bluebird Bio (I); Celgene; Gilead Sciences; Takeda; Tesaro
 
Pingkuan Zhang
Employment - Novartis; Takeda
Stock and Other Ownership Interests - Amgen; BeiGene; GlaxoSmithKline; Novartis
 
D. Ross Camidge
Honoraria - AstraZeneca; bio-thera; Daiichi Sankyo; G1 therapeutics; Genoptix; Hansoh; Ignyta; Lycera; Mersana; Revolution Medicines; Roche; takeda
Research Funding - Takeda